Jiangsu Nhwa Pharmaceutical Co., LTD (SHE: 002262)

Market Cap	24.74B
Revenue (ttm)	5.53B
Net Income (ttm)	1.17B
Shares Out	1.02B
EPS (ttm)	1.16
PE Ratio	20.98
Forward PE	18.59
Dividend	0.32 (1.31%)
Ex-Dividend Date	n/a

Volume	5,745,261
Open	25.06
Previous Close	24.85
Day's Range	24.28 - 25.06
52-Week Range	20.64 - 29.98
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 29, 2025

About Jiangsu Nhwa Pharmaceutical Co., LTD

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. It’s product portfolio includes Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc.; and Iptakalim, an anti-hypertension drug. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs. Jiangsu Nhwa Pharmaceutical Co., LTD was founded in 1978 and is headquartered in Xuzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,394
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2023, Jiangsu Nhwa Pharmaceutical Co., LTD's revenue was 5.04 billion, an increase of 17.28% compared to the previous year's 4.30 billion. Earnings were 1.04 billion, an increase of 15.12%.